Prostamax vs TriMix
A side-by-side research comparison of Prostamax and TriMix across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Prostamax | TriMix |
|---|---|---|
| Full name | Prostamax (Prostate Peptide Bioregulator) | TriMix (Papaverine + Phentolamine + Alprostadil) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound (peptide bioregulator) | Compounded medication |
| Mechanism | As a signal peptide, it is proposed to regulate gene expression in prostate tissue, supporting normal prostatic function, reducing inflammation-related dysfunction, and maintaining healthy urogenital tissue. | Papaverine relaxes smooth muscle via PDE inhibition. Phentolamine blocks alpha-adrenergic receptors. Alprostadil (PGE1) directly stimulates cAMP production in cavernosal tissue. Together they produce reliable penile erection independent of arousal. |
| Molecular weight | ~ (short peptide) | Combination compound |
| Half-life | Short (peptide) | ~1-3 hours (local effect) |
| Bioavailability | Oral (encapsulated) or subcutaneous | Direct intracavernosal: ~100% |
| Typical dose | ~1-2 capsules/day or short injectable courses | 0.1-0.5 mL (titrated) |
| Frequency | Once daily | As needed, max 3x/week |
| Route | Oral capsule or subcutaneous | Intracavernosal injection |
Prostamax reported benefits
- Prostate tissue support (proposed)
- Male urogenital health
- Anti-inflammatory tissue signaling (proposed)
- Short course-based protocol
TriMix reported benefits
- Reliable erectile response
- Works when oral meds fail
- Rapid onset (5-15 min)
- Adjustable dosing
- No systemic cardiovascular effects
Related comparisons
Research and educational reference only. Not medical advice.